| Menorrhagia
Liletta vs Oriahnn
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Liletta vs Oriahnn with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOriahnn has a higher rate of injection site reactions vs Liletta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Oriahnn but not Liletta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Liletta
Oriahnn
At A Glance
Intrauterine
Single insertion
Progestin-releasing IUS
Oral
Twice daily
GnRH receptor antagonist
Indications
- Menorrhagia
- Menorrhagia
- Uterine Fibroids
Dosing
Contraception Single intrauterine insertion; remove by end of eighth year; may be replaced at time of removal for continued contraception.
Menorrhagia Single intrauterine insertion; replace by end of fifth year if continued treatment of heavy menstrual bleeding is needed.
Menorrhagia, Uterine Fibroids One elagolix 300 mg/estradiol 1 mg/norethindrone acetate 0.5 mg capsule orally in the morning and one elagolix 300 mg capsule orally in the evening, for up to 24 months.
Contraindications
- Pregnancy
- Use as post-coital contraception (emergency contraception)
- Congenital or acquired uterine anomaly, including leiomyomas, that distorts the uterine cavity
- Acute pelvic inflammatory disease (PID)
- Postpartum endometritis or infected abortion in the past 3 months
- Known or suspected uterine or cervical malignancy
- Known or suspected breast cancer or other hormone-sensitive cancer, now or in the past
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis, including bacterial vaginosis, chlamydial or gonococcal cervical infection, or other lower genital tract infections until infection is controlled
- Acute liver disease or liver tumor (benign or malignant)
- Conditions associated with increased susceptibility to pelvic infections
- A previously inserted IUS that has not been removed
- History of hypersensitivity reaction to any component of LILETTA
- High risk of arterial, venous thrombotic, or thromboembolic disorders (including women over 35 who smoke and those with history of DVT, pulmonary embolism, vascular disease, thrombogenic cardiac conditions, hypercoagulopathies, uncontrolled hypertension, or migraine with aura over age 35)
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormonally-sensitive malignancies, or increased risk for hormonally-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to ORIAHNN or any of its components
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
Adverse Reactions
Most common (>=5%) Vulvovaginal mycotic infections, vaginal bacterial infections, acne, nausea or vomiting, headache, breast tenderness or pain, abdominal discomfort or pain, dyspareunia, anxiety, depression, pelvic discomfort or pain, dysmenorrhea, mood changes, back pain, weight increased, vaginal discharge
Serious Ectopic pregnancy, ovarian cysts, IUS perforation requiring laparoscopic surgery
Postmarketing Arterial thrombotic and venous thromboembolic events (pulmonary emboli, deep vein thrombosis, stroke), hypersensitivity reactions (rash, urticaria, angioedema), increased blood pressure, dizziness, device breakage
Most common (>=5%) Hot flush, headache, fatigue, metrorrhagia
Serious Thromboembolic and vascular events, bone loss, suicidal ideation and behavior, exacerbation of mood disorders, hepatic transaminase elevations, elevated blood pressure, alopecia, changes in lipid parameters
Pharmacology
Levonorgestrel-releasing intrauterine system; locally released LNG prevents pregnancy by thickening cervical mucus to inhibit sperm passage, inhibiting sperm mobility and capacitation, and altering the endometrium.
GnRH receptor antagonist combination; elagolix competitively binds GnRH receptors in the pituitary gland, suppressing LH and FSH and reducing ovarian estradiol and progesterone, with add-back estradiol/norethindrone acetate to mitigate bone loss and protect the endometrium from unopposed estrogen effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Liletta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Oriahnn
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Liletta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Oriahnn
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Liletta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Oriahnn
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Liletta.
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LilettaView full Liletta profile
OriahnnView full Oriahnn profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.